摘要
目的研究达格列净对2型糖尿病患者生活质量(QOL)的影响。方法选择2018年1—12月本院门诊就诊的二甲双胍治疗失效的2型糖尿病患者120例作为研究对象,随机分成A、B两组,每组各60例。A组予达格列净+二甲双胍治疗,B组予门冬胰岛素30+二甲双胍治疗,两组均视餐后2小时血糖情况加用拜唐苹。测定观察前后糖化血红蛋白(HbA1c)、体质量指数(BMI)等代谢指标,采用SF-36健康调查简表作QOL调查。结果共有A组58例、B组有56例患者完成研究,两组患者观察前所有代谢指标差异无统计学意义(P>0.05);观察后A组2 hPBG优于B组(P<0.05);观察后两组HbA1c差异无统计学意义(P>0.05),但A组HbA1c达标率为86.2%,高于B组的67.9%(P<0.05);观察后A组BMI较B组显著下降(P<0.01)。两组拜唐苹使用例数和平均用量无统计学差异(P>0.05)。观察前两组患者QOL各维度无统计学差异(P>0.05);观察后A组患者QOL相关的8个维度改善均显著优于B组(P<0.05 or 0.01);与观察前相比,A组8个维度显著改善(P<0.05 or 0.01),B组仅4个维度有改善(P<0.05)。结论达格列净有提高2型糖尿病患者生活质量的降糖外获益。
Objective To study the effect of Dapagliflozin on the quality of life(QOL)of patients with type 2 diabetes mellitus.Methods 120 patients with type 2 diabetes mellitus who failed in metformin treatment from January to December 2018 were selected as the study objects,and they were randomly divided into group A and B,60 cases in each group.The patients in group A were treated with Dapagliflozin and metformin,group B were treated with insulin Aspart 30 and metformin.The use of acarbose in both groups was according to 2 hours postprandial blood glucose.Metabolic indexes such as glycosylated hemoglobin(HbA1c)and body mass index(BMI)were measured before and after observation,and QOL was investigated with 36-item short-form health survey(SF-36).Results The study was completed in 58 cases in group A and 56 cases in B group.There was no significant difference in the metabolic indexes between the two groups before observation(P>0.05).After observation,2hPBG in group A was better than that in group B(P<0.05).There was no significant difference in HbA1c between the two groups after observation(P>0.05),but the rate of HbA1c reaching standard in group A(86.2%)was higher than that in group B(67.9%)(P<0.05).After observation,BMI in group A was significantly lower than that in group B(P<0.01).There was no statistical difference between the two groups in the number of acarbose use cases and the average amount between the two groups(P>0.05).There was no difference in the QOL between the two groups before observation(P>0.05).After observation,the improvement of the 8 dimensions related to QOL in group A was significantly better than that in group B(P<0.05 or 0.01).The 8 dimensions of group A were significantly improved compared with those before observation(P<0.05 or 0.01),only 4 dimensions of group B were improved(P<0.05).Conclusions Dapagliflozin has the benefit of improving the QOL in patients with type 2 diabetes mellitus.
作者
韦玉和
薛一
邵雪景
冯小芬
赵志勇
徐瑞君
董茹
WEI Yu-he(Department of endocrinology,Wujin hospital affiliated Jiangsu University,Changzhou,Jiangsu,213002,China.)
出处
《齐齐哈尔医学院学报》
2020年第5期570-572,共3页
Journal of Qiqihar Medical University
关键词
达格列净
2型糖尿病
生活质量
Dapagliflozin
Type 2 diabetes mellitus
Quality of life
